Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized …
LJ van Nimwegen, L de Haan… - The Canadian …, 2008 - journals.sagepub.com
LJ van Nimwegen, L de Haan, NJM van Beveren, M van der Helm, W van den Brink…
The Canadian Journal of Psychiatry, 2008•journals.sagepub.comObjective: To examine whether subjective well-being and craving for cannabis were different
in patients with schizophrenia or related disorders treated with either olanzapine or
risperidone. Method: A 6-week, double-blind, randomized trial of olanzapine and
risperidone was carried out in 128 young adults with recent onset schizophrenia or related
disorders. Primary efficacy measures were the mean baseline-to-endpoint change in total
scores on the Subjective Well-Being under Neuroleptics scale, the Obsessive–Compulsive …
in patients with schizophrenia or related disorders treated with either olanzapine or
risperidone. Method: A 6-week, double-blind, randomized trial of olanzapine and
risperidone was carried out in 128 young adults with recent onset schizophrenia or related
disorders. Primary efficacy measures were the mean baseline-to-endpoint change in total
scores on the Subjective Well-Being under Neuroleptics scale, the Obsessive–Compulsive …
Objective
To examine whether subjective well-being and craving for cannabis were different in patients with schizophrenia or related disorders treated with either olanzapine or risperidone.
Method
A 6-week, double-blind, randomized trial of olanzapine and risperidone was carried out in 128 young adults with recent onset schizophrenia or related disorders. Primary efficacy measures were the mean baseline-to-endpoint change in total scores on the Subjective Well-Being under Neuroleptics scale, the Obsessive–Compulsive Drug Use Scale, the Drug Desire Questionnaire, and the cannabis use self-report. An analysis of covariance was used to test between-group differences.
Results
Estimated D2 receptor occupancy did not differ between olanzapine (n = 63) and risperidone (n = 65). Similar improvements in subjective well-being were found in both groups. In the comorbid cannabis-using group (n = 41, 32%), a similar decrease in craving for cannabis was found in both treatment conditions.
Conclusions
Both olanzapine and risperidone were associated with improved subjective well-being. No evidence was found for a differential effect of olanzapine or risperidone on subjective experience or on craving for cannabis in dosages leading to comparable dopamine D2 occupancy.
Objectif
Examiner si le bien-être subjectif et l'état de manque de cannabis étaient différents chez les patients souffrant de schizophrénie ou de troubles connexes traités à l'olanzapine ou à la rispéridone.
Sage Journals以上显示的是最相近的搜索结果。 查看全部搜索结果